What is the Market's View on Crispr Therapeutics AG (CRSP) Stock's Price and Volume Trends

Friday, January 8, 2021 10:55 AM | InvestorsObserver Analysts

Crispr Therapeutics AG (CRSP) stock has gained 35.58% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bullish
Crispr Therapeutics AG has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CRSP Stock Today?

Crispr Therapeutics AG (CRSP) stock is trading at $207.58 as of 10:53 AM on Friday, Jan 8, an increase of $13.15, or 6.76% from the previous closing price of $194.43. The stock has traded between $196.11 and $210.39 so far today. Volume today is below average. So far 1,482,585 shares have traded compared to average volume of 2,079,604 shares.

To see InvestorsObserver's Sentiment Score for Crispr Therapeutics AG click here.

More About Crispr Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Share this article:

Related Companies

You May Also Like

Related Articles

Sector Update: Health Care Stocks Fading Near Tuesday Bell

Sector Update: Health Care

Pulse Biosciences Inc (PLSE) is down -8.41% in a Week, Should You Hold?

How Does iTeos Therapeutics Inc (ITOS) Stock Rank on Wall Street Tuesday?

Does Akouos Inc (AKUS) Have What it Takes to be in Your Portfolio Tuesday?

Analyst Rating: Will Arcturus Therapeutics Holdings Inc (ARCT) Stock Lead the Market?

Related Companies